Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BMP4 and Temozolomide Synergize in the Majority of Patient-Derived Glioblastoma Cultures.
Verploegh ISC, Conidi A, El Hassnaoui H, Verhoeven FAM, Korporaal AL, Ntafoulis I, van den Hout MCGN, Brouwer RWW, Lamfers MLM, van IJcken WFJ, Huylebroeck D, Leenstra S. Verploegh ISC, et al. Among authors: ntafoulis i. Int J Mol Sci. 2024 Sep 22;25(18):10176. doi: 10.3390/ijms251810176. Int J Mol Sci. 2024. PMID: 39337661 Free PMC article.
Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells.
Fabro F, Kers TV, Feller KJ, Beerens C, Ntafoulis I, Idbaih A, Verreault M, Connor K, Biswas A, Salvucci M, Prehn JHM, Byrne AT, O'Farrell AC, Lambrechts D, Dilcan G, Lodi F, Arijs I, Kremer A, Tching Chi Yen R, Chien MP, Lamfers MLM, Leenstra S. Fabro F, et al. Among authors: ntafoulis i. Int J Mol Sci. 2023 Oct 27;24(21):15678. doi: 10.3390/ijms242115678. Int J Mol Sci. 2023. PMID: 37958662 Free PMC article.
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Ntafoulis I, Kleijn A, Ju J, Jimenez-Cowell K, Fabro F, Klein M, Chi Yen RT, Balvers RK, Li Y, Stubbs AP, Kers TV, Kros JM, Lawler SE, Beerepoot LV, Kremer A, Idbaih A, Verreault M, Byrne AT, O'Farrell AC, Connor K, Biswas A, Salvucci M, Prehn JHM, Lambrechts D, Dilcan G, Lodi F, Arijs I, van den Bent MJ, Dirven CMF, Leenstra S; GLIOTRAIN consortium; Lamfers MLM. Ntafoulis I, et al. Br J Cancer. 2023 Oct;129(8):1327-1338. doi: 10.1038/s41416-023-02402-y. Epub 2023 Aug 24. Br J Cancer. 2023. PMID: 37620410 Free PMC article.
Comparative analysis of deeply phenotyped GBM cohorts of 'short-term' and 'long-term' survivors.
Biswas A, Salvucci M, Connor K, Düssmann H, Carberry S, Fichtner M, King E, Murphy B, O'Farrell AC, Cryan J, Beausang A, Heffernan J, Cremona M, Hennessy BT, Clerkin J, Sweeney KJ, MacNally S, Brett F, O'Halloran P, Bacon O, Furney S, Verreault M, Quissac E, Bielle F, Ahmed MH, Idbaih A, Leenstra S, Ntafoulis I, Fabro F, Lamfers M, Golebiewska A, Hertel F, Niclou SP, Yen RTC, Kremer A, Dilcan G, Lodi F, Arijs I, Lambrechts D, Purushothama MK, Kel A, Byrne AT, Prehn JHM. Biswas A, et al. Among authors: ntafoulis i. J Neurooncol. 2023 Jun;163(2):327-338. doi: 10.1007/s11060-023-04341-3. Epub 2023 May 26. J Neurooncol. 2023. PMID: 37237151 Free PMC article.
Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy.
White K, Connor K, Meylan M, Bougoüin A, Salvucci M, Bielle F, O'Farrell AC, Sweeney K, Weng L, Bergers G, Dicker P, Ashley DM, Lipp ES, Low JT, Zhao J, Wen P, Prins R, Verreault M, Idbaih A, Biswas A, Prehn JHM, Lambrechts D, Arijs I, Lodi F, Dilcan G, Lamfers M, Leenstra S, Fabro F, Ntafoulis I, Kros JM, Cryan J, Brett F, Quissac E, Beausang A, MacNally S, O'Halloran P, Clerkin J, Bacon O, Kremer A, Chi Yen RT, Varn FS, Verhaak RGW, Sautès-Fridman C, Fridman WH, Byrne AT. White K, et al. Among authors: ntafoulis i. Ann Oncol. 2023 Mar;34(3):300-314. doi: 10.1016/j.annonc.2022.11.008. Epub 2022 Dec 6. Ann Oncol. 2023. PMID: 36494005 Free article.
Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures.
Verheul C, Ntafoulis I, Kers TV, Hoogstrate Y, Mastroberardino PG, Barnhoorn S, Payán-Gómez C, Tching Chi Yen R, Struys EA, Koolen SLW, Dirven CMF, Leenstra S, French PJ, Lamfers MLM. Verheul C, et al. Among authors: ntafoulis i. Neurooncol Adv. 2021 Aug 2;3(1):vdab103. doi: 10.1093/noajnl/vdab103. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34595478 Free PMC article.